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Abstract
Introduction: Joint hypermobility is common in childhood and can be associated with musculoskeletal pain and
dysfunction. Current management is delivered by a multidisciplinary team, but evidence of effectiveness is limited.
This clinical trial aimed to determine whether a structured multidisciplinary, multisite intervention resulted in
improved clinical outcomes compared with standard care.
Method: A prospective randomised, single centre parallel group trial comparing an 8-week individualised
multidisciplinary intervention programme (bespoke physiotherapy and occupational therapy in the clinical, home
and school environment) with current standard management (advice, information and therapy referral if deemed
necessary).
The primary endpoint of the study was between group difference in child reported pain from baseline to 12
months as assessed using the Wong Baker faces pain scale. Secondary endpoints were parent reported pain (100
mm visual analogue scale), parent reported function (child health assessment questionnaire), child reported quality
of life (child health utility 9-dimensional assessment), coordination (movement assessment battery for children
version 2) and grip strength (handheld dynamometer).
Results: 119 children aged 5 to 16 years, with symptomatic hypermobility were randomised to receive an
individualised multidisciplinary intervention (I) (n = 59) or standard management (S) (n = 60). Of these, 105
completed follow up at 12 months. No additional significant benefit could be shown from the intervention
compared to standard management. However, there was a statistically significant improvement in child and parent
reported pain, coordination and grip strength in both groups. The response was independent of the degree of
hypermobility.
Conclusion: This is the first randomised controlled trial to compare a structured multidisciplinary, multisite
intervention with standard care in symptomatic childhood hypermobility. For the majority, the provision of
education and positive interventions aimed at promoting healthy exercise and self-management was associated
with significant benefit without the need for more complex interventions.
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Background
Joint hypermobility is common in childhood, with a high
prevalence reported in the literature when adult criteria
are applied [1–7]. Hypermobile joints are not synonym-
ous with morbidity; for example, gymnasts, musicians
and athletes can use this flexibility to their advantage [8,
9]. However, pain has been reported to occur in as many
as 55% of all children with hypermobility [10] and chil-
dren with symptomatic hypermobility account for a large
proportion of referrals to tertiary paediatric rheumatol-
ogy services [11]. Symptomatic hypermobility (previously
referred to as joint hypermobility syndrome (JHS)) is
varied in its presentation and is challenging both to
diagnose and manage, reflected by a wide variation in
practice.
Given the frequency of this presentation there has been a
need to develop consistent approaches to treatment. Man-
agement guidelines produced by The British Society for
Paediatric and Adolescent Rheumatology based on clinical
consensus advocate a multidisciplinary approach including
physiotherapy (PT), occupational therapy (OT) and podiatry
(Additional file 1), with an emphasis on self-management
and delivered in clinical, home and school settings. The
therapeutic interventions are often targeted at increasing
muscle strength and proprioception in the affected joints
and limbs [12–15]. However, objective evidence of their ef-
fectiveness is almost completely lacking [15].
Methods
Objectives
This study aimed to determine the effectiveness of a multi-
disciplinary care package in children diagnosed with symp-
tomatic hypermobility by comparing a structured, bespoke
programme of treatment delivered through a team of
clinicians, physiotherapists and occupational therapists in
clinical, home and school settings, with standard care.
Design
Prospective single centre randomised parallel group trial
comparing an 8-week individualised multidisciplinary,
multisite intervention programme (I) with current stand-
ard care (S).
Setting
Jenny Lind children’s department at the Norfolk and
Norwich University Hospital NHS Trust, UK. This is a
regional centre for paediatric rheumatology referrals.
Patients
Children aged 5–16 years old referred to the paediatric
rheumatology clinic between October 2010 and Novem-
ber 2012 were eligible for inclusion. Referrals came from
community and general paediatrics, orthopaedics, physio-
therapy and occupational therapy and general practice.
Patients were recruited between 7th of January 2011
and 14th of December 2012. The final twelve month
follow-up assessments were conducted between the 5th
of January 2012 and the 20th of December 2013.
Inclusion criteria
The service accepts referrals up to age 16 years old. In
the absence of validated diagnostic criteria for symp-
tomatic childhood hypermobility (or childhood JHS),
children who were experiencing pain, functional or co-
ordination problems considered to be secondary to
hypermobility by an experienced paediatric rheuma-
tologist were invited to take part, who met the follow-
ing criteria:
A minimum Beighton score of 4 or more [16], or Bulbena
score of 5 or more (males) and 6 or more (females) (see
Table 1) [17].
Musculoskeletal pain in one or more areas of the body
for at least 3 months duration.
Exclusion criteria
Participants were excluded if identified by an experienced
consultant paediatric rheumatologist (KA) to have inflam-
matory joint disease, heritable disorder of connective
tissue except Ehlers Danlos hypermobility type, presence
of other chronic illness such as chronic pain syndrome or
chronic fatigue syndrome using available diagnostic
criteria [18–20]. Children under 5 years were excluded,
anticipating they would have difficulty complying with the
home exercise programme. In addition, children were
excluded where, in the clinician’s judgement they were un-
able to comply with the protocol .
Baseline assessments
Assessments were carried out by a designated paediatric
physiotherapist (VE) assisted by the trial coordinator
(LW). Written informed parental consent and patient
assent was obtained. Demographic data were collected
using a standardised questionnaire.
Specific evaluations included an assessment of:
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Joint laxity, clinical evaluation of the extent and
distribution of joint laxity by applying the Beighton
and Bulbena scoring systems (Table 1).
Pain, using the Wong Baker faces pain scale (0–5)
and self-reporting of sites of pain [21]. Children were
asked to report their pain over the previous week.
Parent reported pain, using a visual analogue scale
(VAS) of 0–100.
Physical function, using the Child Health Assessment
Questionnaire (CHAQ) [22].
Health related quality of life (HRQoL) using the
9 dimensional Child Health Utility (CHU9D) [23].
Motor skills and coordination, using the Movement
Assessment Battery for Children version 2 (M-ABC2)
[24, 25].
Grip strength, using a standardised hand held
pneumatic dynamometer (White Plains, New York)
taking 3 readings and recording the highest achieved.
Interventions
All children with confirmed symptomatic hypermobility
were offered standard management and given written in-
formation regarding the study. Those who showed an
interest were contacted by the trial coordinator by tele-
phone after a minimum of 48 h to answer any remaining
questions and determine their willingness to take part.
The trial coordinator contacted families both by telephone
and in writing to achieve maximum retention of partici-
pants throughout the study. If no reply was received or if
3 re-scheduled appointments were not attended they were
considered lost to follow up.
Standard care group
Standard care followed usual practice at the hospital and
consisted of a single paediatric rheumatology clinic ap-
pointment (typically of around 30–40min) with a Paedi-
atric Rheumatologist (KA) who diagnosed symptomatic
hypermobility. All patients and families received verbal
information and advice on management including dis-
cussing the biomechanical origin of the pain, the need
for good muscle strength, examples of appropriate activ-
ities and a standard (Arthritis Research UK) information
leaflet [26]. Referrals to PT, OT and orthotics were made
where deemed clinically necessary.
Multidisciplinary intervention group
The multidisciplinary intervention was developed and
refined by the research team following a systematic re-
view of the literature [27], national consultation with
specialist paediatric rheumatology therapy departments
and informal consensus. The intervention comprised a
programme of 3 individualised physiotherapy sessions
addressing problem areas, and promoting improve-
ments in stability and strength; gait analysis and
provision of foot orthoses if needed; an OT assessment
at the hospital clinic and at home; a joint physiotherapy
and OT school visit to discuss the diagnosis with
teachers and provide advice as necessary for both school
and home. Children were given equipment depending on
their needs. This included: a writing wedge, hand putty,
pen grips, cutlery grips and a laptop computer. Those with
problems in their hands received an OT directed hand ex-
ercise programme. The intervention was conducted by a
Table 1 Classification of hypermobility
Site Criterion Beighton Bulbena
Thumb Apposition to forearm x x
5th Metacarpophalangeal joint Passive hyperextension > 90 degrees x x
Elbow Hyperextension > 10 degrees x x
Knee hyperextension Hyperextension > 10 degrees x
Trunk Flexion to place hands flat on floor with legs straight x
Ankle Dorsiflexion > 20 degrees x
Shoulder External rotation > 85 degrees x
Hip Passive abduction > 85 degrees x
Patella Passive shift to lateral side of tibia x
1st Metatarsophalangeal joint Passive hyperextension > 90 degrees x
Knee flexion Heel to contact buttocks x
Ecchymoses Presence after minimal trauma x
Total point available 9 10
Score to determine hypermobility 4 out of 9 Males 5/10
Females 6/10
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second paediatric physiotherapist (HB) and a paediatric
occupational therapist (EJ). Both had access to baseline
data in order to plan bespoke management.
Details of the specific structure of the intervention are
listed below:
Visit 1 (week 1)
A joint treatment session with the occupational therapist
(EJ) and physiotherapist (HB). Children were given an
individualised programme of exercise devised to target
symptomatic joints and problem areas. Exercises were
selected from the PhysioTools© manual. Information
packs were supplied, and an orthotic appointment was
arranged if deemed necessary.
Visit 2 (week 2)
An OT review at home which included an assessment of
activities of daily living, use of aids, sleep, and leisure
pursuits.
Visit 3 (week 4)
A school visit by both the physiotherapist and OT. This
included the delivery of an education information pack
and an assessment of difficulties in this environment.
The child’s overall mobility around school, handwriting,
physical education, and school attendance was discussed
with teachers, the child was not provided with any treat-
ment on this visit.
Visits 4 and 5 (weeks 6 and 8)
These visits took place at the Jenny Lind Children’s
Physiotherapy department at the Norfolk and Norwich
University Hospital and were undertaken by the trial
physiotherapist (HB). The assessments reviewed the indi-
vidual exercise programme initiated on week 1 and adapted
and progressed treatment as necessary.
Main outcome measures
Outcome measures
The primary outcome measure was child reported pain
(Wong-Baker scales). The secondary outcomes were
parent-reported pain (100mm VAS), physical function
(CHAQ), HRQoL, coordination and grip strength. School
attendance and requirement for health interventions were
also recorded.
Primary and secondary outcome measures were
assessed at 3 and 12months after the baseline assessment.
These outcomes were evaluated by trial physiotherapist
(VE) who was blinded to the intervention group. Parents
and children were specifically asked not to discuss their
treatment with VE.
Sample size
It was estimated that we would need to randomise 100
children to either of the two treatment arms to detect a
0.5 SD change in pain score between the intervention
and the standard care groups (at a nominal one-sided
significance of 0.05 and 80% power). This was estimated
using the sample size commands in STATA statistical
software [28]. We aimed to recruit 125 children to ac-
commodate a 20% drop out rate anticipated from previ-
ous reported trials. No adjustment for multiple testing
was made.
Randomisation
The treatment groups were allocated randomly with
minimisation used to achieve balance in group charac-
teristics. The trial coordinator used a bespoke computer
based method in the CTU remote from the research
team. Three variables were utilised: age, gender and par-
ent reported pain level.
Statistical methods
As over 90% of the sample attended all assessments, an
intention to treat complete case analysis was conducted.
Comparisons were made between the two groups for
data that related to the 12-month period starting at the
date that the first assessment was completed.
Between group comparisons were carried out in
primary and secondary outcome measures for the dif-
ferences between baseline values and values at three
months and 12 months and baseline by t-tests for un-
adjusted analysis and linear regression models for ana-
lysis adjusted for age.
An ancillary analysis was conducted to examine the
change in primary and secondary outcome measures
over time. Multilevel regression modelling was used,
with fixed effects for intervention, time and treatment x
time, and random effects for the intercepts at each time
point. The analyses were conducted using the STATA
statistical software version 12 [28].
Ethical approval
The study was approved by the Norfolk Research ethics
committee 09/H0310/80 on the 23rd of December 2009.
Results
A total of 157 children were assessed for eligibility by
the paediatric rheumatologist (KA). Of these 38 were
not randomised: 11 did not meet the eligibility criteria
and 27 declined consent.
As illustrated in Fig. 1, 119 children were rando-
mised, and 59 (50%) received the intervention. Of these,
111 attended 3 month follow up and 105 attended 12
month follow up. Of the 59 randomised to the inter-
vention, 56 (93.3%) completed the multidisciplinary,
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multisite programme. All 56 attended 3 month follow
up and 54 (91.5%) attended 12 month follow up. Of the
60 randomised to receive standard care, 55 (91.7%)
were assessed at 3 months and 51 (85%) at 12 months.
Overall the drop out was 6% at 3 months and a further
6% at 12 months.
Characteristics of the sample
The children’s characteristics at their baseline assess-
ment are shown in Table 2 and show no important dif-
ferences between the two groups.
Outcomes at 3 and 12months
Table 3 shows the between group differences in child
pain as assessed by the Wong-Baker Faces scale between
three months and baseline, and between 12months and
baseline. The level of pain improved in both groups at
each of the follow up assessments; however, there was
no significant difference in improvement between the
two groups. A small improvement in child reported pain
at 3 months was seen in the standard care group com-
pared to the intervention group in the age adjusted data.
Table 3 lists between group comparisons with baseline
assessment for parent reported pain, parent reported
Fig. 1 Participant flow through study
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physical function, HRQoL, coordination and grip strength.
No change was observed in the child reported HRQoL
score (CHU9D) between groups or in either group
throughout the study period. Coordination improved
more than expected for age related gains at 3months, but
was not generally sustained at a year. As might be ex-
pected grip strength improved with age. None of the dif-
ferences between groups was significant.
Rate change in outcomes over time
The multilevel regression model is shown in Table 4 and
shows a significant mean improvement in child and
parent reported pain, coordination and grip strength
over the 12 months of follow up across the intervention
and the standard care group taken together. However,
neither the intervention itself, nor any of the individual
patient characteristics considered separately (age, gender,
Table 2 Baseline demographic and clinical data, including hypermobility and symptom scores
Characteristics Intervention
(n = 59)
Standard care
(n = 60)
Gender: male, n (%) 27.0 (45.8) 27.0 (45.0)
Age in years, mean (SD) 9.47 (3.18) 9.35 (3.20)
BMI, mean (SD) 18.9 (4.54) 18.0 (2.92)
Family history of JHS, n (%) 11 (18.6) 17.0 (28.3)
Child’s pain assessment, mean (SD) 2.19 (1.36) 2.53 (1.63)
Parent’s pain assessment, mean (SD) 33.8 (24.8) 40.6 (27.5)
Parent’s reported physical function, mean (SD) 0.84 (0.620) 0.860 (0.72)
Child reported HRQoL, mean (SD) 0.85 (0.100) 0.850 (0.12)
Coordination, mean centile (SD) 33.4 (26.7) 35.6 (30.1)
Grip strength (kilopascals), mean (SD) 57.0 (25.0) 59.4 (31.7)
Beighton, mean (SD) 5.80 (1.50) 5.70 (1.40)
Bulbena, mean (SD) 7.40 (1.60) 7.70 (1.30)
Number of painful joints, mean (SD) 1.80 (2.1) 2.10 (2.50)
Participation in sport (number of sessions per week), mean (SD) 2.60 (2.30) 2.60 (2.40)
Absence from school due to MSK problem (individual instances in last 3 months), mean (SD) 1.10 (3.30) 0.630 (2.10)
GP attendance for MSK problem (individual instances in last 3 months), mean (SD) 0.320 (0.800) 0.380 (0.880)
Hospital attendance due to MSK problem (individual instances in last 3 months), mean (SD) 1.10 (0.800) 1.47 (1.41)
Table 3 Differences in primary and secondary outcomes at 3 and 12 months
Factor Standard care Intervention Unadjusted mean difference p-value Adjusted mean difference p-value
3 Months change from baseline (outcome – baseline)
Child’s pain assessment, mean (SD) −1.33 (1.69) −0.73 (1.55) 0.6 (− 0.02,1.22) 0.058 0.62 (0.04,1.21) 0.038
Parent’s pain assessment mean (SD) −6.73 (26.26) −3.27 (28.64) 3.46 (−6.88,13.8) 0.509 3.36 (−7.01,13.72) 0.522
Parent’s reported physical function,
mean (SD)
−0.02 (0.38) 0.13 (0.52) 0.15 (−0.02,0.33) 0.088 0.15 (−0.02,0.32) 0.089
Child reported HRQoL, mean (SD) 0.00 (0.10) 0.01 (0.11) 0.01 (−0.03,0.05) 0.493 0.01 (−0.03,0.05) 0.492
Coordination, mean (SD) 7.57 (20.26) 6.21 (19.54) −1.36 (−8.88,6.16) 0.721 −1.36 (−8.92,6.19) 0.721
Grip strength, mean (SD) 2.32 (12.03) 1.12 (13.87) −1.2 (−6.18,3.78) 0.634 −1.21 (− 6.19,3.77) 0.632
12 Months change from baseline (outcome – baseline)
Child’s pain assessment, mean (SD) −1.58 (1.92) −1.57 (1.53) 0.01 (−0.66,0.69) 0.967 0.06 (−0.6,0.71) 0.862
Parent’s pain assessment mean (SD) −7.25 (29.50) −6.81 (27.30) 0.44 (−10.55,11.43) 0.937 −0.08 (−10.94,10.78) 0.988
Parent-reported physical function,
mean (SD)
−0.02 (0.38) 0.04 (0.55) 0.06 (−0.12,0.24) 0.522 0.06 (−0.13,0.24) 0.546
Child reported HRQoL, mean (SD) −0.00 (0.12) 0.02 (0.09) 0.02 (−0.02,0.06) 0.244 0.03 (−0.02,0.07) 0.222
Coordination, mean (SD) 10.75 (19.46) 3.83 (20.75) −6.92 (−14.76,0.92) 0.083 −6.87 (− 14.75,1.02) 0.087
Grip strength, mean (SD) 7.29 (16.05) 4.72 (17.16) −2.58 (−9.05,3.89) 0.431 −2.59 (−9.1,3.92) 0.432
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body mass index, and baseline degree of hypermobility)
had a statistically significant impact on the rate of
improvement over time. The self-reported baseline level
of pain was a statistically significant determinant of
12-month outcome, with higher levels of baseline pain
associated with more rapid mean reduction in pain score
over time. A similar effect was seen for parent reported
pain although it did not reach statistical significance.
Discussion
This randomised, single centre parallel group trial com-
pared a structured multidisciplinary, multisite interven-
tion programme with standard care in children with
symptomatic hypermobility. No added benefit was seen
from this intervention. Both treatment groups showed
improvements in child and parent reported pain scores,
coordination and grip strength after one year follow up.
The self-reported HRQoL (as assessed by CHU9D) did
not change in either group through the period of follow
up. Our HRQoL scores for both groups remained within
the normal reference range for healthy children [29, 30],
suggesting that while children with symptomatic hyper-
mobility experience a degree of pain and motor impair-
ment, these symptoms tend not to limit their overall
wellbeing compared to their healthy peers.
Clinicians faced with diagnosing and planning treatment
for children with hypermobility and pain currently have
very sparse evidence on which to base their decisions. A
systematic review [27] identified only three robust studies
on the management of hypermobility [14, 31, 32], only
two of which were conducted in the paediatric popula-
tion [14, 32] and just one was a randomised compara-
tive trial [14]. The non-randomised studies conducted
in children were limited in their scope and targeted sin-
gle joint-specific areas associated with hypermobility
(knee proprioception and handwriting) [31, 32]. The
single randomised trial focused on physiotherapy and
compared targeted with a general programme of treat-
ment. As in our own study, children showed an im-
provement in pain through follow up with no evidence
to favour any particular management strategy. However,
interpretation is limited by the small size (57 partici-
pants) and consequent lack of power, and low retention
rate (just 56%). The influence of a fuller range of inter-
ventions that might be delivered by the multidisciplin-
ary team has not been addressed.
The present study was designed to address the potential
value of a multidisciplinary, multisite intervention pack-
age. Our intervention was developed through systematic
literature review and clinical consensus, and adheres to
the current British Society for Paediatric and Adolescent
Rheumatology guidance. The intervention was designed
for efficient delivery in a general hospital and community
setting in a limited time.
This study has important limitations. We adopted a
pragmatic approach to diagnosis, utilising a ‘real world’
clinical setting, and included children that an experi-
enced paediatric rheumatologist diagnosed with symp-
tomatic hypermobility. In taking this approach, we feel
that the participants included reflect the broad range of
the population referred to paediatric secondary and
tertiary care and subsequently diagnosed with symptom-
atic hypermobility. Diagnostic criteria for JHS or
Ehlers-Danlos hypermobility type (now termed hyper-
mobility spectrum disorders and hypermobile EDS) [33,
34] have not been validated in the paediatric population.
We applied Bulbena and Beighton scoring systems to con-
firm generalised hypermobility, to add face validity and to
facilitate comparison with other published studies. The
cut off values used conform to published literature, how-
ever population data on joint hypermobility scores across
all age groups is still lacking. Higher cut off scores have
been suggested but not validated [1, 34, 35].
All participants received at least ‘standard care’ as an
ethical requirement and could not be blinded to the inter-
ventions, which require active engagement. Participants
gave fully informed consent and were therefore aware of
the interventions in the treatment arm, which may have
influenced behaviour. The trial coordinator recorded the
number of therapy attendances in the preceding 3months
at each follow up appointment in all participants to ensure
that the assessing physiotherapist (VE) remained fully
blinded. We are aware that in the standard care arm 36
children (60%) received at least one additional session of
physiotherapy or occupational therapy and five received
orthotics. Inevitably those randomised to the standard
care group, irrespective of additional sessions, received a
greater degree of attention than might have occurred out-
side an interventional trial.
We did not include direct measurement of child or
parental anxiety in our study protocol. A systematic re-
view of the literature conducted by our group has shown
an association between anxiety and pain in children with
hypermoblity [36]. It is possible that a reduction in anx-
iety due to clarification of the condition and education
could have resulted in the improvements in pain seen
across both groups.
A further limitation is the lack of validated outcome
measures for symptomatic hypermobility in childhood.
The pain measure used in the study assessed the inten-
sity at the most prominent site and did not reflect the
variable nature of pain or the variation in sites over the
period assessed. The CHAQ is an assessment tool for
children with juvenile idiopathic arthritis. It has not been
validated for use in symptomatic hypermobility but has
been used in a previous study [14]. It is conceivable that
the outcome measures used may lack adequate sensitiv-
ity to detect a difference between the interventions. It is
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also possible that the sample size may have limited our
ability to detect differences between the two intervention
groups.
This study does not address whether hypermobile chil-
dren report more pain compared to their non-hypermobile
peers. In the multilevel model, there was no direct relation-
ship between pain and degree of hypermobility and the de-
gree of hypermobility was not related to level of symptom
improvement or response to treatment. The data suggest
that the relationship between the degree of joint mobility
and a child’s experience of pain is not direct.
Conclusions
We conclude that for children presenting with symp-
tomatic hypermobility, standard care offered in routine
practice in the UK is sufficient to lead to a sustained
improvement in symptoms over a twelve-month period
and that a more intensive multidisciplinary approach
offers little further benefit. We recognise that symp-
tomatic hypermobility is a heterogeneous condition and
there may be subgroups that differ sufficiently to bene-
fit from more intensive intervention [37, 38]. Neverthe-
less, our results suggest that for the majority the
provision of education and positive interventions aimed
at promoting healthy exercise and self-management
leads to significant benefit without the need for more
complex interventions. We believe our findings will
help the development of prompt, simple and effective
approaches to management, and will help diffuse beliefs
about disability and negative consequences of this
condition.
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